NMDP Data Shows Strong Outcomes Across Diverse Donor Types in Cell Therapy
Event summary
- NMDP presented new research at EBMT 2026 showing two-year outcomes for 13,336 U.S. transplants across different donor types.
- Matched sibling donors (MSDs) had the highest overall survival (70%) and lowest GVHD rates, but alternative donors showed strong results.
- OPTIMIZE trial interim findings revealed differences in immune recovery based on conditioning intensity post-MMUD transplant.
- ACCESS trial data confirmed that mismatched unrelated donor (MMUD) transplants using PTCy achieved comparable outcomes to fully matched donors.
The big picture
NMDP's research underscores the evolving landscape of cell therapy, where innovations like PTCy are expanding donor eligibility and improving outcomes for blood cancer patients. The data supports broader adoption of alternative donors, addressing a critical gap in access for patients without fully matched siblings. This shift aligns with industry trends toward personalized medicine and optimized transplant protocols.
What we're watching
- Donor Expansion Impact
- How the validation of alternative donor options will affect patient access to transplants globally.
- Immune Recovery Insights
- Whether further research on immune recovery post-MMUD transplant can refine supportive care strategies.
- PTCy Adoption Pace
- The pace at which post-transplant cyclophosphamide (PTCy) becomes standard in diverse transplant settings.